Through a blood sample, the test can detect antibodies to the new coronavirus, which could signal a person may have already been infected. (Copyright 2020 The Associated Press. All Rights Reserved.) The US Food and Drug Administration (FDA) has given emergency approval for use of the serological test developed by Swiss pharmaceutical giant Roche, the company announced on Sunday. The test is designed to determine whether a person has been exposed to the new coronavirus and developed antibodies against the disease. The Basel-based firm says that its Elecsys Anti-SARS-CoV-2 test has a specificity rate of 99.8% – which lowers the chance of false positives – and detects antibodies with 100% sensitivity. Roche has started shipping the new test to laboratories around the
Topics:
Swissinfo considers the following as important: 3) Swiss Markets and News, 3.) Swiss Info, Featured, newsletter, Sci & Tech, Sci & Tech
This could be interesting, too:
Marc Chandler writes Sterling and Gilts Pressed Lower by Firmer CPI
Ryan McMaken writes A Free-Market Guide to Trump’s Immigration Crackdown
Wanjiru Njoya writes Post-Election Prospects for Ending DEI
Swiss Customs writes Octobre 2024 : la chimie-pharma détermine le record à l’export
The US Food and Drug Administration (FDA) has given emergency approval for use of the serological test developed by Swiss pharmaceutical giant Roche, the company announced on Sunday.
The test is designed to determine whether a person has been exposed to the new coronavirus and developed antibodies against the disease.
The Basel-based firm says that its Elecsys Anti-SARS-CoV-2 test has a specificity rate of 99.8% – which lowers the chance of false positives – and detects antibodies with 100% sensitivity.
Roche has started shipping the new test to laboratories around the world and says it plans to increase production to “high dougle-digit millions per month” to supply countries that accept the CE mark as well as the US.
Scientists worldwide are in a race to develop serological tests, as results can help policy-makers better understand the disease, determine who may have had the virus and who may have immunity, and what measures may still be needed to fight the pandemic.
Tags: Featured,newsletter,Sci & Tech